Who Should Be Monitored for Ozempic-Related Gastroparesis in Washington?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specialized Risk Awareness

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, these could be early signs of gastroparesis. Understanding who is at higher risk and what symptoms warrant medical attention is critical for timely intervention. This page reviews the clinical red flags Washington patients should know, building on a long tradition of informed patient-provider communication about medication risks.

Transition to Ozempic Exposure and Gastroparesis Risk

The transition to examining Ozempic exposure and gastroparesis risk requires careful attention to the legal and regulatory frameworks that govern patient safety. In Washington State, the statute of limitations for product liability claims related to such exposures imposes strict time constraints on affected individuals seeking legal recourse. Understanding these temporal boundaries is essential for those who may have experienced adverse outcomes following prescribed use, as the window for filing a claim is finite and varies based on the date of injury or discovery. This pivot from general health information to specific exposure concerns underscores the need for precise, actionable guidance within a neutral academic framework.

Clinical Evidence Linking Ozempic to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its mechanism of action includes slowing gastric emptying, which is integral to its therapeutic effect but also raises concerns about gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis can be diagnosed through gastric emptying scintigraphy or breath tests, and symptoms often overlap with common gastrointestinal adverse effects of Ozempic. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistic pathways linking Ozempic to gastroparesis involve its action on GLP-1 receptors in the gastrointestinal tract, which slows gastric motility. This effect is dose-dependent and can persist beyond the intended therapeutic window. Postmarketing reports have documented pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This indicates that delayed gastric emptying can be severe enough to pose aspiration risk, a complication of gastroparesis. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Rybelsus or Ozempic tablets, including whether modifying preoperative fasting recommendations or temporarily discontinuing these drugs could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Adequacy of Warnings and Legal Context in Washington

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk anchor. The prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not address the potential for gastroparesis to develop as a chronic condition. This gap in warnings may affect patients who experience persistent symptoms after discontinuation of the drug. For affected patients in Washington, attorney-related considerations include the statute of limitations for product liability claims. In Washington, the statute of limitations for personal injury claims is generally three years from the date of injury or discovery of the injury. For claims involving harm from a medication, the timeline between exposure and documented harm is critical. Patients who developed gastroparesis after starting Ozempic should document the date of first use, onset of symptoms, and any medical diagnosis of gastroparesis. The statute of limitations may begin when the patient knew or should have known that the injury was caused by Ozempic. Given that gastrointestinal symptoms are common and may be initially attributed to other causes, the discovery date could be later than the actual onset of harm. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of their case, including the adequacy of warnings and the timing of their injury. The evidence suggests that gastrointestinal adverse reactions are common with Ozempic, and the risk of gastroparesis may be underrecognized. The postmarketing reports of pulmonary aspiration underscore the potential severity of delayed gastric emptying. However, the prescribing information does not explicitly warn of gastroparesis, which could be a basis for a failure-to-warn claim. In summary, the clinical presentation of gastroparesis overlaps with common gastrointestinal effects of Ozempic, and mechanistic pathways support a causal link. The adequacy of warnings is questionable given the absence of explicit mention of gastroparesis. Patients in Washington should be aware of the three-year statute of limitations and the importance of documenting the timeline between exposure and harm. Legal consultation is recommended to assess individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Washington?

In Washington, the statute of limitations for personal injury claims, including product liability for medications, is generally three years from the date of injury or discovery of the injury. For Ozempic-related gastroparesis, the clock may start when the patient knew or should have known that the injury was caused by Ozempic. It is crucial to document the timeline of exposure, symptom onset, and diagnosis.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic lists gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but does not explicitly warn of gastroparesis as a distinct adverse event. This gap in warnings may be relevant for patients who develop chronic delayed gastric emptying after using Ozempic.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.